Draft Guidances Describe FDA’s Interim Plans for Bulk Drugs Used for Compounding

The FDA has released two draft guidances with interim policies addressing the FDA’s efforts to finalize bulk drug lists for compounders subject to 503A regulations and for compounders using bulk substances under 503B regulations.
Source: Drug Industry Daily